NCT00785954 - Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack] | Biotech Hunter

Enrollment

1,180

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

May 31, 2011

Conditions

Myocardial InfarctionCardiovascular DiseasesPathologic Processes

Interventions

DRUG

KAI-9803

STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo

Trial Locations (126)

14221

Williamsville

15009

Beaver

17822

Danville

27262

High Point

27410

Greensboro

30309

Atlanta

33613

Tampa

35801

Huntsville

43701

Zanesville

46383

Valparaiso

60148

Lombard

60515

Downers Grove

61602

Peoria

68131

Omaha

77030

Oklahoma City

90509

Torrance

92025

Escondido

Unknown

Bedford Park

Boxhill

Epping

Fremantle

Hobart

Kogarah

Liverpool

Parkville

Perth

St Leonards

Victoria

Antwerp

Bonheiden

Brussels

Liège

Roeselare

Edmonton

Vancouver

Hamilton

Kitchner

Newmarket

Toronta

Toronto

Montreal

Sainte-Foy

New Brunswick

Brno

Hradec Králové

Karlovy Vary

Labem

Liberec

Olomouc

Ostrava

Pilsen

Prague

Zlín

Aalborg

Copenhagen

Hellerup

Odense

Helsinki

Turku

Berlin

Halle

Hamburg

Heidelberg

Lübeck

Magdeburg

Mannheim

München

Rostock

Budapest

Pécs

Szeged

Székesfehérvár

Zalaegerszeg

Afula

Ashkelon

BeerSheva

Haifa

Holon

Jerusalem

Kfar Saba

Safed

Ẕerifin

Pesaro

Rome

Rozzano

Amsterdam

Nieuwegein

Rotterdam

Zwolle

Auckland

Christchurch

Dunedin

Hamilton

Nelson

Arendal

Bergen

Bialystok

Bielsko-Biala

Dąbrowa Górnicza

Gdansk

Gdynia

Krakow

Lubin

Poznan

Szczecin

Torun

Warsaw

Almada

Amadora

Carnaxide

Alicante

Barcelona

El Palmar Murcia

León

Madrid

Santa Cruz de Tenerife

Seville

Vigo Pontevedra

Gothenburg

Helsingborg

Linköping

Lund

Malmo

Örebro

Stockholm

Sundsvall